VALIDATING DIAGNOSTICS
TO COMBAT ANTIMICROBIAL RESISTANCE BY
OPTIMISING ANTIBIOTIC USE
OPTIMISING ANTIBIOTIC USE
Previous slide
Next slide
VALUE-Dx Closing Conference
The VALUE-Dx project is coming to an end soon, and to mark this momentous occasion, a closing conference will be held on 4 – 5 September. More info here.
ADEQUATE & PRUDENCE
The recruitment face of the ADEQUATE and PRUDENCE trials has successfully reached its targets!
SUBSCRIBE TO OUR NEWSLETTER
Social Media
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 820755. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and bioMérieux SA, Janssen Pharmaceutica NV, Abbott, Bio-Rad Laboratories, BD Switzerland Sàrl, and The Wellcome Trust Limited.